Pricara- PAIN Division

Quote
Anonymous said:
NEVER! i would rather have 1 new drug that the company's willing to put money behind than 4 old ones.... r u kidding? Levaquin- gone, aciphhex-old hasbeen that never really was. i know, i launched it. so what ur left with docs don't even need to hear about....ur job has zero worth, therefore neither do u. there r plenty of opportunities still unchartered specialties with nucynta. plus, i have no samples less bullshit, less tracking. u want to be me.
Click to expand...
What samples are you talking about. I stopped getting them a year ago.
 




Anonymous said:
NEVER! i would rather have 1 new drug that the company's willing to put money behind than 4 old ones.... r u kidding? Levaquin- gone, aciphhex-old hasbeen that never really was. i know, i launched it. so what ur left with docs don't even need to hear about....ur job has zero worth, therefore neither do u. there r plenty of opportunities still unchartered specialties with nucynta. plus, i have no samples less bullshit, less tracking. u want to be me.
Click to expand...

Aren't you guys due for a layoff?
 








Anonymous said:
NEVER! i would rather have 1 new drug that the company's willing to put money behind than 4 old ones.... r u kidding? Levaquin- gone, aciphhex-old hasbeen that never really was. i know, i launched it. so what ur left with docs don't even need to hear about....ur job has zero worth, therefore neither do u. there r plenty of opportunities still unchartered specialties with nucynta. plus, i have no samples less bullshit, less tracking. u want to be me.
Click to expand...

Eventually the company will see that after 2 years, the pain sales force still can't pay their own salaries with the amount of rx's they sell. This will end their ride.
 








The current model for promoting drugs in unsustainable. Paying sales people six fugures, plus benefits, cars, gas, expenses to bring lunches to offices, and/or give thirty econd soundbites is incredibly wasteful. We all know that access is horrible, so really what are they paying us for. The bottomline is that with technology, mor efficient means of product promotions will become more and more prevalent, and doctors will increasingly ask "what am I getting out of this". The reality is that beyond the launch phase of a drug, the drug rep really brings very little value to an office. Thats just the truth! This profession is a dying one, and if you are under the age of fifty, you had better have a plan "B", because you are going to need it. You had also better ne saving your bloated salaries, because we are likely the most overpaid profession in the world. There is no job that a drug rep can build on. As we lose our jobs, and we all will, 99% of us will be no better than a new college grad.
 




Anonymous said:
The current model for promoting drugs in unsustainable. Paying sales people six fugures, plus benefits, cars, gas, expenses to bring lunches to offices, and/or give thirty econd soundbites is incredibly wasteful. We all know that access is horrible, so really what are they paying us for. The bottomline is that with technology, mor efficient means of product promotions will become more and more prevalent, and doctors will increasingly ask "what am I getting out of this". The reality is that beyond the launch phase of a drug, the drug rep really brings very little value to an office. Thats just the truth! This profession is a dying one, and if you are under the age of fifty, you had better have a plan "B", because you are going to need it. You had also better ne saving your bloated salaries, because we are likely the most overpaid profession in the world. There is no job that a drug rep can build on. As we lose our jobs, and we all will, 99% of us will be no better than a new college grad.
Click to expand...

Lucky are the few who make 6 figures. Most PriCara reps don't make 6 figures for base. Comp plans are not paying out like they used to.

I disagree that there are no jobs that drug reps can build on. Every layoff proves this theory wrong. Many go on to do all kinds of meaningful jobs -- Medical sales (disposables, device, EMR, Managed Care companies, Wholesaler Pharma, Generics) . . .
 
























Why do people always try to say they are better if they are specialty vs primary care vs Hospital. We all do the same thing. Most of the pain reps ended up as pain reps because they had less time with the company and got put in that division instead of getting laid off. We are all equal. There are good reps and bad reps in both. There are tenured high salary and new low salary in both. We are all in the same boat. We are all worried about our jobs. We all have bills and families to take care of. Why do people have to belittle other to make them feel better about this mess we are all in together. Just wake up everyday and say a prayer that we still get paid before you go to work.
 




Grünenthal is Proving Itself in Pain

The need for abuse resistant tamper-resistant formulations is making good use of Grünenthal's technology which is being licensed out, but not yet FDA approved - to Endo Pharmaceuticals Inc. for use with a long-acting version of that company's pain drug OpanaER (oxymorphone) and Johnson & Johnson for TapentadolER.

In February 2009, Endo paid $28.5 million upfront to Grünenthal and committed about three times as much again in milestones for U.S. and Canadian rights to Phase II axomadol for moderate-to-severe chronic pain and diabetic peripheral neuropathy.

And in December 2010, Forest licensed U.S. and Canadian rights to a Phase II liquid formulation of morphine from Grünenthal, along with a pre-clinical follow-on, for $66.1 million upfront. Both compounds are opioid receptor-like-1/mu opioid agonists. Hitting both these receptors has been shown to produce a synergistic pain-relieving effect.

Grünenthal also has a non-narcotic opioid compound that should reach proof-of-concept by 2012, according to Stock.
 




Anonymous said:
Grünenthal is Proving Itself in Pain

The need for abuse resistant tamper-resistant formulations is making good use of Grünenthal's technology which is being licensed out, but not yet FDA approved - to Endo Pharmaceuticals Inc. for use with a long-acting version of that company's pain drug OpanaER (oxymorphone) and Johnson & Johnson for TapentadolER.

In February 2009, Endo paid $28.5 million upfront to Grünenthal and committed about three times as much again in milestones for U.S. and Canadian rights to Phase II axomadol for moderate-to-severe chronic pain and diabetic peripheral neuropathy.

And in December 2010, Forest licensed U.S. and Canadian rights to a Phase II liquid formulation of morphine from Grünenthal, along with a pre-clinical follow-on, for $66.1 million upfront. Both compounds are opioid receptor-like-1/mu opioid agonists. Hitting both these receptors has been shown to produce a synergistic pain-relieving effect.

Grünenthal also has a non-narcotic opioid compound that should reach proof-of-concept by 2012, according to Stock.
Click to expand...

J&J faces thalidomide boycott due to Ties with Grünenthal
By Andrew Jack, London Published: Feb 27 2011 20:28

Johnson & Johnson, the US healthcare company, faces the threat of a consumer boycott from campaigners who suffered birth defects 50 years ago caused by the morning sickness drug thalidomide created by Grünenthal.

Nick Dobrik, a member of the national advisory council to the UK’s Thalidomide Trust, said he was preparing a boycott and demonstrations against J&J in escalating efforts to seek compensation from Grünenthal, the German manufacturer of the drug, with which the US group has strong US commercial links.

The action is the latest effort by “thalidomiders” from the UK, Canada and Scandinavia to seek significant funding from Grünenthal, which was recently sued in Australia.

It would prove a fresh embarrassment to J&J, which is already suffering US congressional scrutiny. Its image has also been under attack over the past year following recalls, triggered by manufacturing problems identified by US regulators, of several top-selling consumer brands.

In 2006 J&J agreed joint development and commercialisation of Grünenthal’s tapentadol (Nucynta), a painkiller on sale since 2009. Grünenthal has argued that it followed the regulations for drug testing in force at the time, withdrawing thalidomide after the side-effects were identified. It paid compensation to those in Germany, leaving its foreign licence holders to defend against litigation elsewhere.

“We have expressed at several occasions that it is a matter of moral importance to Grünenthal to be actively involved in charitable efforts to improve the situation of thalidomide victims on a sustainable basis,” the company said. “It is of moral importance to us to seek to work together with thalidomide victims to devise projects for the provision of specific needs-based support.”

Mr Dobrik, who has escalated his campaigning after saying Grünenthal has launched a website called “stop the tears” – a reference to J&J’s “no more tears” slogan for baby products. “The fact that Grünenthal has still not provided any financial assistance to UK thalidomiders sums up the attitude of the pharma industry,” he said.

Copyright The Financial Times Limited 2011
 








Just learned from a CVS Pharmacist that they STOPPED reporting data to IMS and that CVS is a lawsuit with IMS (great - most of my Pharmacies are CVS).

So I Googled this and here's what it says,

March 10, 2011, Federal Regulations will soon prohibit the collection and dissemination of prescription data, data mining for profit.

Costco, Walmart, Target and several other medium sized pharmacy chains already DO NOT report data. CVS is ending their contract at this time.
 




Anonymous said:
The current model for promoting drugs in unsustainable. Paying sales people six fugures, plus benefits, cars, gas, expenses to bring lunches to offices, and/or give thirty econd soundbites is incredibly wasteful. We all know that access is horrible, so really what are they paying us for. The bottomline is that with technology, mor efficient means of product promotions will become more and more prevalent, and doctors will increasingly ask "what am I getting out of this". The reality is that beyond the launch phase of a drug, the drug rep really brings very little value to an office. Thats just the truth! This profession is a dying one, and if you are under the age of fifty, you had better have a plan "B", because you are going to need it. You had also better ne saving your bloated salaries, because we are likely the most overpaid profession in the world. There is no job that a drug rep can build on. As we lose our jobs, and we all will, 99% of us will be no better than a new college grad.
Click to expand...

Dead right. Pharma leads nowhere. There are few jobs that logically follow a career in pharma sales and people generally look down on pharma salespeople as having never really "sold" because they have nothing to do with contracting, pricing, and servicing after sale.

People who go on to get good jobs in devices and other medically-related fields are the exception to the rule, and anyone who actually had the 6-figure salary has 1) a harder time getting a new job and 2) a near-zero chance of getting a similar comp plan.
 








Why hasn't JnJ done any studies to support that Nucynta is a better options for patients that have a history of addiction due to better withdraw rates and discontinuation rates?

Nucynta's MOA supports. And hey, there's not much st. value for it & patients never run out early.


Do you agree?
 




Top Bottom
Back
Quote